TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomized Clinical Trial in Juvenile Fibromyalgia
Brief Summary: Juvenile fibromyalgia is a chronic pain condition that can cause considerable suffering and difficulty in an adolescent's day-to-day activities. The purpose of this study is to determine whether coping skills training, when combined with usual medical care, can reduce pain and disability in adolescents with fibromyalgia.

Study hypotheses: 1) Adolescents who receive coping skills training combined with their usual medical care will show significantly greater reductions in functional disability, pain, and depressive symptoms at the end of the acute treatment phase than adolescents who receive fibromyalgia education with their usual medical care. 2) Adolescents who receive coping skills training with their usual medical care will show significantly lower levels of functional disability, pain, and depressive symptoms at the end of a six-month maintenance phase than adolescents who receive fibromyalgia education with their usual medical care.


Options:
A: Change in FDI (Functional Disability Inventory) Scores at End of Study (Baseline and 6 months (end of study))
B: Headache diaries assess headache frequency. (Completed one month prior to first visit, then weekly up to Week 20, then one month prior to Month 3, 6, 9, and 12 Follow-Up Visits.)
C: Juvenile Arthritis Quality of Life Questionnaire (JAQQ) (Baseline (prior to randomization) and 3 months after intervention)
D: Adherence (beginning at baseline - week 20)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomized Clinical Trial in Juvenile Fibromyalgia
Brief Summary: Juvenile fibromyalgia is a chronic pain condition that can cause considerable suffering and difficulty in an adolescent's day-to-day activities. The purpose of this study is to determine whether coping skills training, when combined with usual medical care, can reduce pain and disability in adolescents with fibromyalgia.

Study hypotheses: 1) Adolescents who receive coping skills training combined with their usual medical care will show significantly greater reductions in functional disability, pain, and depressive symptoms at the end of the acute treatment phase than adolescents who receive fibromyalgia education with their usual medical care. 2) Adolescents who receive coping skills training with their usual medical care will show significantly lower levels of functional disability, pain, and depressive symptoms at the end of a six-month maintenance phase than adolescents who receive fibromyalgia education with their usual medical care.


Options:
A: Headache diaries assess headache frequency. (Completed one month prior to first visit, then weekly up to Week 20, then one month prior to Month 3, 6, 9, and 12 Follow-Up Visits.)
B: Metabolic Control: Hemoglobin A1c (HbA1c) (2 years)
C: symptoms of recurrent abdominal pain (measured one week following treatment and again in 3, 6 and 12 months); disability (measured one week following treatment and again in 3, 6 and 12 months)
D: Change in FDI (Functional Disability Inventory) Scores at End of Study (Baseline and 6 months (end of study))

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomized Clinical Trial in Juvenile Fibromyalgia
Brief Summary: Juvenile fibromyalgia is a chronic pain condition that can cause considerable suffering and difficulty in an adolescent's day-to-day activities. The purpose of this study is to determine whether coping skills training, when combined with usual medical care, can reduce pain and disability in adolescents with fibromyalgia.

Study hypotheses: 1) Adolescents who receive coping skills training combined with their usual medical care will show significantly greater reductions in functional disability, pain, and depressive symptoms at the end of the acute treatment phase than adolescents who receive fibromyalgia education with their usual medical care. 2) Adolescents who receive coping skills training with their usual medical care will show significantly lower levels of functional disability, pain, and depressive symptoms at the end of a six-month maintenance phase than adolescents who receive fibromyalgia education with their usual medical care.


Options:
A: Juvenile Arthritis Quality of Life Questionnaire (JAQQ) (Baseline (prior to randomization) and 3 months after intervention)
B: Change in FDI (Functional Disability Inventory) Scores at End of Study (Baseline and 6 months (end of study))
C: Headache diaries assess headache frequency. (Completed one month prior to first visit, then weekly up to Week 20, then one month prior to Month 3, 6, 9, and 12 Follow-Up Visits.)
D: symptoms of recurrent abdominal pain (measured one week following treatment and again in 3, 6 and 12 months); disability (measured one week following treatment and again in 3, 6 and 12 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomized Clinical Trial in Juvenile Fibromyalgia
Brief Summary: Juvenile fibromyalgia is a chronic pain condition that can cause considerable suffering and difficulty in an adolescent's day-to-day activities. The purpose of this study is to determine whether coping skills training, when combined with usual medical care, can reduce pain and disability in adolescents with fibromyalgia.

Study hypotheses: 1) Adolescents who receive coping skills training combined with their usual medical care will show significantly greater reductions in functional disability, pain, and depressive symptoms at the end of the acute treatment phase than adolescents who receive fibromyalgia education with their usual medical care. 2) Adolescents who receive coping skills training with their usual medical care will show significantly lower levels of functional disability, pain, and depressive symptoms at the end of a six-month maintenance phase than adolescents who receive fibromyalgia education with their usual medical care.


Options:
A: ER visits (18 months)
B: Metabolic Control: Hemoglobin A1c (HbA1c) (2 years)
C: Parental asthma-related quality of life (one year); Urgent care events for asthma (One year)
D: Change in FDI (Functional Disability Inventory) Scores at End of Study (Baseline and 6 months (end of study))

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomized Clinical Trial in Juvenile Fibromyalgia
Brief Summary: Juvenile fibromyalgia is a chronic pain condition that can cause considerable suffering and difficulty in an adolescent's day-to-day activities. The purpose of this study is to determine whether coping skills training, when combined with usual medical care, can reduce pain and disability in adolescents with fibromyalgia.

Study hypotheses: 1) Adolescents who receive coping skills training combined with their usual medical care will show significantly greater reductions in functional disability, pain, and depressive symptoms at the end of the acute treatment phase than adolescents who receive fibromyalgia education with their usual medical care. 2) Adolescents who receive coping skills training with their usual medical care will show significantly lower levels of functional disability, pain, and depressive symptoms at the end of a six-month maintenance phase than adolescents who receive fibromyalgia education with their usual medical care.


Options:
A: Change in FDI (Functional Disability Inventory) Scores at End of Study (Baseline and 6 months (end of study))
B: HbA1c (Change from Baseline to 3 months and from 3 months to 6 months)
C: Reduction in symptoms of depression (change from baseline) (12 weeks and 52 weeks)
D: Change from Baseline in CDI at 14 weeks (Week 0, Week 14)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Randomized Clinical Trial in Juvenile Fibromyalgia
Brief Summary: Juvenile fibromyalgia is a chronic pain condition that can cause considerable suffering and difficulty in an adolescent's day-to-day activities. The purpose of this study is to determine whether coping skills training, when combined with usual medical care, can reduce pain and disability in adolescents with fibromyalgia.

Study hypotheses: 1) Adolescents who receive coping skills training combined with their usual medical care will show significantly greater reductions in functional disability, pain, and depressive symptoms at the end of the acute treatment phase than adolescents who receive fibromyalgia education with their usual medical care. 2) Adolescents who receive coping skills training with their usual medical care will show significantly lower levels of functional disability, pain, and depressive symptoms at the end of a six-month maintenance phase than adolescents who receive fibromyalgia education with their usual medical care.


Options:
A: Change in FDI (Functional Disability Inventory) Scores at End of Study (Baseline and 6 months (end of study))
B: Parent Report Measures (4 years)
C: ER visits (18 months)
D: symptoms of recurrent abdominal pain (measured one week following treatment and again in 3, 6 and 12 months); disability (measured one week following treatment and again in 3, 6 and 12 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of 8% Progesterone Vaginal Gel in Preventing Preterm Delivery in Pregnant Women at Increased-Risk for Preterm Delivery
Brief Summary: This research study is being conducted at over 12 pregnancy research centers in the US. The study will compare an investigational treatment with a placebo (a treatment without medication). Neither the investigators nor the patients in the trial will know which treatment has been assigned. All study medications will be given vaginally once a day. Treatment will begin before pregnancy week 23 and will continue until the end of pregnancy week 36.


Options:
A: Delivery prior to 35 weeks 0 days gestation (Delivery Date)
B: Weeks Gestation at Birth Among Patients Receiving the Active Drug. (Through delivery, until discharge up to 40 weeks gestation)
C: Frequency of delivery <=32 weeks (18 weeks gestation through delivery)
D: Spontaneous delivery before 34 completed weeks (238 days) of gestation.

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of 8% Progesterone Vaginal Gel in Preventing Preterm Delivery in Pregnant Women at Increased-Risk for Preterm Delivery
Brief Summary: This research study is being conducted at over 12 pregnancy research centers in the US. The study will compare an investigational treatment with a placebo (a treatment without medication). Neither the investigators nor the patients in the trial will know which treatment has been assigned. All study medications will be given vaginally once a day. Treatment will begin before pregnancy week 23 and will continue until the end of pregnancy week 36.


Options:
A: Spontaneous Delivery Before 34 Completed Weeks (Between 24 and 34 weeks)
B: The frequency of spontaneous abortion before 28 weeks (14 weeks)
C: Frequency of delivery <=32 weeks (18 weeks gestation through delivery)
D: Preterm delivery (Less than 34 weeks gestation)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of 8% Progesterone Vaginal Gel in Preventing Preterm Delivery in Pregnant Women at Increased-Risk for Preterm Delivery
Brief Summary: This research study is being conducted at over 12 pregnancy research centers in the US. The study will compare an investigational treatment with a placebo (a treatment without medication). Neither the investigators nor the patients in the trial will know which treatment has been assigned. All study medications will be given vaginally once a day. Treatment will begin before pregnancy week 23 and will continue until the end of pregnancy week 36.


Options:
A: Weeks Gestation at Birth Among Patients Receiving the Active Drug. (Through delivery, until discharge up to 40 weeks gestation)
B: The incidence of delivery < 34 weeks, in the study group versus the control group (Participants will be followed until 3 weeks after delivery)
C: Delivery prior to 35 weeks 0 days gestation (Delivery Date)
D: Frequency of delivery <=32 weeks (18 weeks gestation through delivery)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy, Safety, and Tolerability of 8% Progesterone Vaginal Gel in Preventing Preterm Delivery in Pregnant Women at Increased-Risk for Preterm Delivery
Brief Summary: This research study is being conducted at over 12 pregnancy research centers in the US. The study will compare an investigational treatment with a placebo (a treatment without medication). Neither the investigators nor the patients in the trial will know which treatment has been assigned. All study medications will be given vaginally once a day. Treatment will begin before pregnancy week 23 and will continue until the end of pregnancy week 36.


Options:
A: The incidence of delivery < 34 weeks, in the study group versus the control group (Participants will be followed until 3 weeks after delivery)
B: Spontaneous delivery before 34 completed weeks (238 days) of gestation.
C: Weeks Gestation at Birth Among Patients Receiving the Active Drug. (Through delivery, until discharge up to 40 weeks gestation)
D: Frequency of delivery <=32 weeks (18 weeks gestation through delivery)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Evaluating Paliperidone Extended Release Tablets in the Prevention of Recurrence in Subjects With Schizophrenia
Brief Summary: The purpose of this study is to determine the efficacy (effectiveness) and safety of paliperidone ER compared with placebo in the prevention of recurrence of symptoms of schizophrenia.


Options:
A: Time to Exacerbation of Psychotic Symptoms/Impending Relapse (Baseline of the depot maintenance phase to the end of the study (Week 52))
B: Time to recurrence, defined as the time between randomization to treatment in the double-blind period and the first documentation of a recurrence.
C: Time From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse in Phase C. (From randomization to time of exacerbation of psychotic symptoms/impending relapse - up to 52 weeks)
D: Percentage of Patients Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria by the End of Week 26 (Baseline to Week 26)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Maintaining Nonsmoking: Older Smokers
Brief Summary: The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.


Options:
A: smoking cessation (6-months)
B: Participants Abstinent From Cigarettes (Two years)
C: The Number of Participants Reporting 7 Day Point Prevalence Abstinence (12-months); Change in Perceived Stress Scores (Baseline, 4 weeks); Change in Depressive Symptoms Scores (Baseline, 4 weeks)
D: Smoking Abstinence (3 months); Smoking Abstinence (6 months); Smoking Abstinence (12 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Maintaining Nonsmoking: Older Smokers
Brief Summary: The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.


Options:
A: Time to Occurrence of Major Adverse Cardiovascular Event (MACE) During Treatment Period (up to Date of Last Dose of Study Drug) in Study NCT01456936. (Baseline to last dose of study drug in parent study NCT01456936 (up to 12 weeks).)
B: Continuous 4-week Abstinence From Smoking Between Weeks 8-11 After the Quit Date (Through the End of Treatment) (weeks 8-11 after quit date)
C: Biochemically verified 7 day point prevalence abstinence from smoking.
D: Participants Abstinent From Cigarettes (Two years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Maintaining Nonsmoking: Older Smokers
Brief Summary: The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.


Options:
A: 7-Day Point Prevalence Abstinence From Smoking by Intervention (26 weeks after the target quit smoking date); 7-Day Point Prevalence Abstinence From Smoking by Nicotine Replacement Therapy (NRT) Group (26 weeks after the target quit smoking date)
B: Continuous Abstinence From Smoking at Ten Weeks Post-quit (May 2009)
C: 6 Month Smoking Abstinence (6 months after smoking quit date); 12 Month Smoking Abstinence (12 months after smoking quit date)
D: Participants Abstinent From Cigarettes (Two years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Maintaining Nonsmoking: Older Smokers
Brief Summary: The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.


Options:
A: Participants Abstinent From Cigarettes (Two years)
B: Continuous 4-week Abstinence From Smoking Between Weeks 8-11 After the Quit Date (Through the End of Treatment) (weeks 8-11 after quit date)
C: Biochemically Verified 7-day Point Prevalence Abstinence (End of Treatment (week 24))
D: N/A

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Maintaining Nonsmoking: Older Smokers
Brief Summary: The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.


Options:
A: Cigarette use (8 weeks)
B: Treatment Satisfaction (End of treatment (seven weeks after baseline))
C: effectiveness (2 years)
D: Participants Abstinent From Cigarettes (Two years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Maintaining Nonsmoking: Older Smokers
Brief Summary: The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.


Options:
A: A significant percentage of surgical patients will be receptive to smoking cessation interventions in the preadmission clinic and will refrain from smoking at 24 and 52 weeks after starting the treatment. (2 years)
B: Number of Participants Completing Continuous Four-week Abstinence From Smoking Between the 8-week and 11-week Post Quit Day Visits (Period between 8-week and 11-week visits post target Quit Day)
C: Participants Abstinent From Cigarettes (Two years)
D: 7-Day Point Prevalence Smoking Abstinence (24 weeks); Continuous Smoking Abstinence (24 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Maintaining Nonsmoking: Older Smokers
Brief Summary: The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.


Options:
A: smoking cessation (date of surgery)
B: 7-day point prevalence of smoking six months following completion of the intervention protocol (nine months post randomization). (2 years)
C: Participants Abstinent From Cigarettes (Two years)
D: 3-month cessation rate

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Maintaining Nonsmoking: Older Smokers
Brief Summary: The purpose of this study was to examine pharmacological and psychological interventions for smokers over 50.


Options:
A: Participants Abstinent From Cigarettes (Two years)
B: The Fagerstrom Test for Nicotine Dependence, expired CO level, and urine cotinine will be used to determine if bupropion SR, when used as an adjunct to antipsychotic medication, is superior to placebo for helping patients with schizophrenia improve their (Expired CO weekly, Fagerstrom baseline and end of study, Urine cotinine baseline, week 2 and week 8); Neuropsychological testing will be used to determine the effects of smoking cessation on patient's attention and memory function. (Beginning and end of study)
C: Continuous 4-week Abstinence From Smoking Between Weeks 8-11 After the Quit Date (Through the End of Treatment) (weeks 8-11 after quit date)
D: 4 week Continuous Quit Rate ( 4 week CQR ) for Weeks 9 -12.

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Comparing Smoking Treatment Programs for Lighter Smokers
Brief Summary: The purpose of this study was to compare two different types of Food and Drug Administration (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in conjunction with two levels of counseling. It was hypothesized that the higher level of counseling would have the highest rates of treatment completion and highest rates of abstinence.


Options:
A: Smoking Behavior (2)
B: Percent Treatment Sessions Attended (52 weeks)
C: Cotinine-validated 7-day point prevalence tobacco abstinence at 1 year follow-up; Cotinine-validated 7-day point prevalence tobacco abstinence at 3 month follow-up (end of treatment)
D: 7-day point prevalence abstinence measured at 6 months (6 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Comparing Smoking Treatment Programs for Lighter Smokers
Brief Summary: The purpose of this study was to compare two different types of Food and Drug Administration (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in conjunction with two levels of counseling. It was hypothesized that the higher level of counseling would have the highest rates of treatment completion and highest rates of abstinence.


Options:
A: Biochemically-confirmed 7-Day Point-Prevalence Abstinence at 26 Weeks (Assessed 26 weeks after the target quit day.)
B: Number of Participants With Smoking Abstinence at Month 6 (Month 6)
C: Percent Treatment Sessions Attended (52 weeks)
D: Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco (Weeks 9 through 12)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Comparing Smoking Treatment Programs for Lighter Smokers
Brief Summary: The purpose of this study was to compare two different types of Food and Drug Administration (FDA) approved smoking cessation medications (nicotine patch or bupropion) used in conjunction with two levels of counseling. It was hypothesized that the higher level of counseling would have the highest rates of treatment completion and highest rates of abstinence.


Options:
A: Hamilton Depression Rating Scale (Ham-D) (Week 8); Memory Saccadic Positional Error, Degrees (Week 8); Predictive Pursuit Gain (Week 8); Maintenance Pursuit Gain (Week 8); Digit Symbol Test (Week 0, Week 2 and Week 8); Conner's Continuous Performance Test (CPT) Detectability Score (Week 0, Week 2 and Week 8); Antisaccade Error Rates (Week 0, Week 2 and Week 8); P50 (Week 0, Week 2 and Week 8)
B: Biochemically verified 7 day point prevalence abstinence from smoking.
C: Percent Treatment Sessions Attended (52 weeks)
D: 7-Day Point Prevalence Abstinence From Smoking by Intervention (26 weeks after the target quit smoking date); 7-Day Point Prevalence Abstinence From Smoking by Nicotine Replacement Therapy (NRT) Group (26 weeks after the target quit smoking date)

Answer: C